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Deriving stage at diagnosis from multiple
population-based sources: colorectal and lung
cancer in England
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1Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
Background: Stage at diagnosis is a strong predictor of cancer survival. Differences in stage distributions and stage-specific
management help explain geographic differences in cancer outcomes. Stage information is thus essential to improve policies for
cancer control. Despite recent progress, stage information is often incomplete. Data collection methods and definition of stage
categories are rarely reported. These inconsistencies may result in assigning conflicting stage for single tumours and confound the
interpretation of international comparisons and temporal trends of stage-specific cancer outcomes. We propose an algorithm that
uses multiple routine, population-based data sources to obtain the most complete and reliable stage information possible.
Methods: Our hierarchical approach derives a single stage category per tumour prioritising information deemed of best quality
from multiple data sets and various individual components of tumour stage. It incorporates rules from the Union for International
Cancer Control TNM classification of malignant tumours. The algorithm is illustrated for colorectal and lung cancer in England. We
linked the cancer-specific Clinical Audit data (collected from clinical multi-disciplinary teams) to national cancer registry data. We
prioritise stage variables from the Clinical Audit and added information from the registry when needed. We compared stage
distribution and stage-specific net survival using two sets of definitions of summary stage with contrasting levels of assumptions
for dealing with missing individual TNM components. This exercise extends a previous algorithm we developed for international
comparisons of stage-specific survival.
Results: Between 2008 and 2012, 163 915 primary colorectal cancer cases and 168 158 primary lung cancer cases were diagnosed
in adults in England. Using the most restrictive definition of summary stage (valid information on all individual TNM components),
colorectal cancer stage completeness was 56.6% (from 33.8% in 2008 to 85.2% in 2012). Lung cancer stage completeness was
76.6% (from 57.3% in 2008 to 91.4% in 2012). Stage distribution differed between strategies to define summary stage. Stage-
specific survival was consistent with published reports.
Conclusions: We offer a robust strategy to harmonise the derivation of stage that can be adapted for other cancers and data
sources in different countries. The general approach of prioritising good-quality information, reporting sources of individual TNM
variables, and reporting of assumptions for dealing with missing data is applicable to any population-based cancer research using
stage. Moreover, our research highlights the need for further transparency in the way stage categories are defined and reported,
acknowledging the limitations, and potential discrepancies of using readily available stage variables.
Stage at diagnosis is a key predictor of cancer survival (Richards,
2009). Differences in stage are believed to be one of the main
drivers of disparities in cancer survival between and within regions
(Sant et al, 2003). England is known to lag behind in cancer
survival in comparison to other comparably wealthy countries with
a universal health system (Coleman et al, 2011). Part of this
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survival differential is presumably due to a poorer stage
distribution of cancer cases in England (Sant et al, 2003; Walters
et al, 2013b). In the past couple of decades, many resources have
been invested in improving cancer outcomes through identifying
and treating cancer at an earlier stage (Richards, 2009; Department
of Health, 2011).
Research examining national and international temporal and
geographical patterns in cancer outcomes is usually based on
population-based cancer registry data, which have historically
lacked information on stage. Further granularity of information is
required to understand in depth the effect of stage on cancer
outcomes at the population level and to monitor and evaluate
cancer policy and changes in clinical practice. Recent efforts by
Public Health England (PHE) and the National Cancer Registra-
tion Service have driven an improvement in availability of stage
information for cancers diagnosed in England (McPhail et al,
2015). The national aim is for at least 70% of cancer patients to be
staged at diagnosis (Health and Social Care Information Centre,
2015).
Clinical or surgical quality assurance programmes, also called
clinical audits, have been developed as instruments to ensure
clinical quality standards of health-care providers (van Gijn et al,
2010). Clinical audits contain detailed clinical data, including
information on diagnostic investigations, stage at diagnosis, and
treatment for cancer (van Gijn et al, 2012). Besides helping clinical
specialists improve their practice, clinical audits offer a rich,
complementary source of clinical data for population-based cancer
research.
Comparability of stage information from different sources has
been a controversial issue, especially when making international or
temporal comparisons, as clinical protocols, data collection
methods, coding practices, and tumour classification systems
may vary between geographies and time periods (Walters et al,
2013a). Inconsistencies may also occur between different sources of
information from the same country.
We describe an algorithm to derive stage at diagnosis from
different sources, based on a series of hierarchical rules applied on
both the data sources and the individual stage variables from the
TNM classification (Sobin et al, 2009). This extends the algorithm
proposed and used by Walters et al (2013a) for the International
Cancer Benchmarking Partnership module 1 study. The algorithm
is illustrated for colorectal and lung cancer.
MATERIALS AND METHODS
Data sources. The National Cancer Registry data provides
information on date of birth, sex, vital status, date of death,
tumour site, and morphology (Office for National Statistics, 2015).
The Cancer Analysis System (CAS) is a national database
administered by the National Cancer Intelligence Network of PHE.
It combines the National Cancer Registry data with data from
other sources (Health and Social Care Information Centre, 2015)
and holds information on main tumour features, socio-demo-
graphic characteristics, stage, and treatment dates.
The National Clinical Audit Programme comprises multiple
clinical audits to monitor and evaluate health-care practice on
specific conditions, benchmark performance, and inform patients
and the general public of current standards of care in different
medical specialties (Healthcare Quality Improvement Partnership,
2015). Cancer clinical audits contain information on patient
referral, diagnostic investigations, pretreatment staging, treatment,
pathology evaluations, posttreatment follow-up, and outcomes.
Information is collected at the hospital level and its accuracy and
completeness should, in principle, be ensured by relevant clinicians
before submission to the Audit (Scott et al, 2014). The National
Bowel Cancer Audit Project (NBOCAP) was developed to collate
detailed clinical bowel cancer data by the Association of
Coloproctology of Great Britain in 2001 (Health and Social Care
Information Centre, 2014). The Lung Cancer Audit Database
(LUCADA) was developed by the Royal College of Physicians
Intercollegiate Lung Cancer Group in 2002 and started collecting
lung cancer data nationally in 2005 (Royal College of Physicians,
2015). Figure 1 summarises the sources of information for the stage
algorithm.
Data linkage. Individual colorectal and lung cancer records from
the ONS National Cancer Registry data were linked to the CAS
records of the same cancers diagnosed between 2008 and 2012. It
followed a two-part strategy, linking records at the patient level
using an eight-level hierarchy based on the availability of
information on NHS number, date of birth, sex, and postcode
and linking records at the tumour level by tumour site and
diagnosis date. Of the 163 915 colorectal cancer cases (ICD-10
C18-C19) in the ONS National Cancer Registry data diagnosed in
England during the study period, 158 953 (96.97%) linked to a CAS
record and 121 707 (74.25%) linked to an NBOCAP record. For
lung cancer (ICD-10 C33-C34), there were 168 158 tumours
diagnosed in England during the study period. Of these, 167 236
(99.45%) linked to a CAS record and 131 540 (78.22%) linked to a
LUCADA record.
The staging algorithm. The algorithm is based on rules of the
Union for International Cancer Control TNM classification of
malignant tumours. The TNM classification was developed in the
1950s as an international standard for classifying malignant
tumours by anatomical extent (Sobin et al, 2009). It aims to
provide an unambiguous grouping of cancer cases for clinicians to
make standardised and consistent decisions for adequate disease
management.
The anatomical extent of disease is based on the assessment of
three components: the extent of the primary tumour (T), the
presence and extent of metastases to regional lymph nodes (N),
and the presence of distant metastases (M). For each tumour, two
classifications are defined: a pretreatment clinical classification (c),
drawn from physical examination, imaging tests, endoscopy,
or biopsy; and a pathological classification (p), after histopatho-
logical assessment of the primary tumour, removal and assess-
ment of lymph nodes, and microscopic evaluation of distant
metastases.
The TNM classification goes through periodic prospective and
retrospective evaluations that lead to the development and
publication of improved editions. The Fifth and Sixth Editions
were published in 1997 and 2002, respectively (Sobin and
Wittekind, 1997, 2002), followed by the current Seventh Edition,
in effect since 2010 (Sobin et al, 2009). Possibly the biggest change
between the latest editions was the elimination of the category Mx,
previously used to denote that distant metastases could not be
assessed (Sobin et al, 2009). This category is now considered
inappropriate as clinical assessment of metastases may be based
solely on physical examination (cM). Pathological Mx (pMx) may
be misinterpreted and overused by pathologists when they have
access to histological material to assess pT and pN, but not for pM,
a frequent situation after surgery for resection of the primary
tumour (Sobin and Compton, 2010). The deletion of this category
encourages the use of M0 when metastasis cannot be proven and
should facilitate the completeness of stage grouping.
Hierarchies of data sources and stage variables. A hierarchy of
data sources was established for different types of information to
avoid inconsistencies, given that information could potentially
come from a maximum of three data sets. The ONS National
Cancer Registration data was our preferred data set for main
person and basic tumour characteristics such as date of birth, vital
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status, deprivation quintile, topography, and morphology of the
primary tumour. This decision was based on their established
quality-control processes to verify this information and to be
consistent with official national cancer statistics (Office for
National Statistics, 2015). Clinical audits were the preferred source
for detailed clinical data such as pretreatment diagnostic
investigations, dates and results of medical interventions, and
staging resulting from these. Staging information from CAS was
used if missing or invalid from the clinical audit.
The algorithm can be divided into two parts for descriptive
purposes. The first part entails deriving individual T, N, and M
components from all available sources of pathological and clinical
stage information. Once individual T, N, and M components have
been ascertained, the second part of the algorithm applies TNM
definitions for stage grouping, to obtain the overall grouped TNM
stage (I, II, III, IV). Two different strategies for deriving TNM stage
grouping are described depending on the acceptable level of
missing information from individual T, N, and M components.
Deriving individual T, N, and M components. We used a set of
rules to treat potentially discordant information from different
sources to derive overall individual T, N, and M components from
different types of variables in the data sets following TNM
classification rules.
The pathological TNM classification uses information from
clinical TNM and complements it using additional information
from pathological evaluation (Sobin et al, 2009). Pathological TNM
should therefore be the most complete source of staging
information, at least for T and N. In our data sets, there was
information for pathological and clinical individual T, N, and M
components from the clinical audits and CAS plus staging
information from additional variables (Table 1). We gave priority
to the pathological variables over clinical ones for T and N, but cM
was prioritised over pM (Walters et al, 2013a). Although distant
metastases are not generally evaluated during surgery for resection
of the primary tumour (Sobin and Compton, 2010; Walters et al,
2013a), pathological confirmation of metastases, from a biopsy, for
example, was given priority over a negative or inconclusive result
from a clinical/imaging test.
Our algorithm allowed results from medical tests and diagnostic
procedures to inform individual clinical T, N, and M components
when missing or with a value of zero. Similarly, records of the
presence of metastases in specific organs or of regional lymph node
involvement were used to inform cM or pN, respectively.
Information in these additional variables was used as evidence of
local, regional, and/or distant extension of disease when positive
but did not rule out their presence. For example, if there was
evidence of distant metastases from one of these additional
variables, this replaced the value of cM to cM1; however, if there
was no evidence of metastasis in that variable, it did not change the
value of cM to cM0, allowing the algorithm to keep looking for
information in subsequent variables.
In addition to the clinical and pathological T, N, and M
components, CAS reports a third type of staging information that
may come from either pathological or clinical data and may use the
highest value of a particular component for a given tumour or be
directly flagged by the registry. This ‘integrated’ stage information
was used only when exhausting all other possible sources because
its algorithm was not fully documented.
We used an additional step for determining the M component
to account for the fact that, although the categories Mx and pM0
do not exist in the Seventh Edition of the TNM classification, their
use is still common practice: If M was still missing after looking in
all potential sources, and there was indirect evidence of a clinical
examination, that is information on both clinical T and N, M was
assumed to be M0. Once an individual overall T, N, or M
ONS
CAS
Clinical audit
Results from pre-treatment
tests (CT, MRI),
Date of birth,
sex,
vital status,
date of last news
(survival)
Person identifier,
main tumour
characteristics*
Pathological and 
clinical TNM 
components,
summary stage
Results from pathological
tests (positive nodes)
Figure 1. Sources of data for deriving stage for colorectal and lung cancer, England, 2008–2012. *Main tumour characteristics include ICD-10
topography codes, histology, behaviour, and date of diagnosis. Abbreviations: CAS¼Cancer Analysis System; CT¼ computarised tomography
scan; MRI¼magnetic resonance imaging; ONS¼Office for National Statistics Cancer Registration Dataset.
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component was populated at a specific step of the algorithm, there
was generally no need to look further for information of that
particular component in subsequent steps of lower priority.
Deriving the grouped TNM stage. After ascertaining individual –
and unique – T, N, and M values to each tumour, the second part
of the algorithm followed TNM classification definitions to
categorise different combinations of T, N, and M values into
TNM stage groupings. This part of the algorithm starts by
examining M. Generally, for most cancer sites, including colorectal
and lung, a positive M value effectively represents the maximum
value of TNM stage grouping, stage IV, independently of the values
of N and T. Similarly, once a positive M has been excluded,
and there is a positive N, the algorithm assigns a TNM stage III to
the tumour, independently of the value of T. The algorithm
then evaluates subsequent subcategories in a descending order
(stages II and I).
To manage the missing information within N and/or M, we
applied two different strategies to derive overall stage based on the
algorithm for deriving stage described by Walters et al (2013a). The
most conservative of the two approaches, the restrictive strategy, is
stricter in the sense that all three components need to be present to
derive the grouped stage. In contrast, the non-restrictive strategy
allows for the interpretation of missing information as an absence
of metastases to the lymph nodes (N) or to distant organs (M).
Additionally, after exhausting all possibilities of deriving the
grouped TNM stage from individual T, N, and M components, the
algorithm moves on to using the pathological and clinical
summary stage information. The restrictive strategy differs in that
we ignore the grouped stage variables, given that we cannot verify
individual T, N, and M components from these.
The staging algorithm applied to colorectal cancer. Both CAS
and NBOCAP use the Fifth Edition of the TNM classification
(Sobin and Wittekind, 1997), following guidance from the Royal
College of Pathologists (Health and Social Care Information
Centre, 2014). The definition of node involvement changed in later
editions, specifically in that evaluation of satellite mesenteric
Table 1. Sources of valid T, N, and M components: completeness of variables and contribution to final staging
Data sets Colorectal Lung
Variables Audit CAS
Completeness
count (%)
Contribution
count (%)
Completeness
count (%)
Contribution
count (%)
T component
pT K 32 648 (19.9) 32 017 (19.5)a 15427 (9.2) 15 427 (9.2)
Serosal involvement or perforation K 5209 (3.2) 710 (0.4) NA NA
pT K 77 997 (47.6) 52 761 (32.2) 14 933 (8.9) 5970 (3.6)
cT K 48 204 (29.4) 16 113 (9.8) 107 171 (63.7) 89 265 (53.1)
Result from MRI K 22 056 (13.5) 2295 (1.4) NA NA
cT K 5773 (3.5) 754 (0.5) 7952 (4.7) 1217 (0.7)
iT K 104 047 (63.5) 11 358 (6.9) 91 917 (54.7) 11 437 (6.8)
Missing T component 47 907 (29.2) 44 842 (26.7)
N component
pN K 32 666 (19.9) 32 518 (19.8)a 15177 (9.0) 15 177 (9.0)
Count of positive lymph nodes K 14 523 (8.9) 310 (0.2) NA NA
pN K 74 212 (45.3) 49 351 (30.1) 15 180 (9.0) 6914 (4.1)
Count of positive lymph nodes K 35 695 (21.8) 4656 (2.8) 3511 (2.1) 841 (0.5)
cN K 50 108 (30.6) 16 141 (9.9) 107 300 (63.8) 88 336 (52.5)
Result from MRI K 20 387 (12.4) 1319 (0.8) NA NA
cN K 6576 (4.0) 1261 (0.8) 8085 (4.8) 1274 (0.8)
iN K 101 453 (61.9) 9574 (5.8) 91 693 (54.5) 11 349 (6.7)
Missing N component 48 785 (29.8) 44 267 (26.3)
M component
cM K 51 542 (31.4) 50 548 (30.8)a 107057 (63.7) 107 057 (63.7)
Distant metastasis K 17 890 (10.9) 8727 (5.3) NA NA
Result from liver CT K 75 714 (46.2) 1064 (0.6) NA NA
cM K 13 212 (8.1) 6548 (4.0) 8987 (5.3) 1894 (1.1)
pM K 10 333 (6.3) 3248 (2.0) 10 845 (6.4) 648 (0.4)
pM K 10 936 (6.7) 4170 (2.5) 9675 (5.8) 2944 (1.8)
iM K 67 948 (41.5) 18 800 (11.5) 92 930 (55.3) 14 197 (8.4)
Clinical examination 3294 (2.0) 3056 (1.8)
Missing M component 67 516 (41.2) 38 362 (22.8)
Summary stageb
pStage K 30 239 (18.4)c 2206 (1.3)c 16946 (10.1) 20 (o0.01)
cStage K 80 036 (48.8)c 1098 (0.7)c 105410 (62.7) 485 (0.3)
pStage K 4351 (2.7) 38 (o0.01) 2117 (1.3) 41 (o0.01)
cStage K 508 (0.3) 5 (o0.01) 679 (0.4) 7 (o0.01)
iStage K 57 596 (35.1) 1189 (0.7) 85 267 (50.7) 1520 (0.9)
Stage K 108 105 (66.0)d 4003 (2.4)d NA NA
Total 163 915 168158
Abbreviations: CAS¼Cancer Analysis System; M¼metastases; MRI¼magnetic resonance imaging; N¼ lymph nodes; NA¼ not available; T¼ tumour. Colorectal and lung cancer diagnoses in
England, 2008–2012. Prefixes: p: pathological; c: clinical; i: integrated (origin may be pathological, clinical, highest value, or simply flagged by the registry).
aSome zero values for this variable are replaced by positive values in the next step of the algorithm, where the contribution to final staging is made. Therefore, completeness of this variable
does not equal its contribution to final staging.
bSummary stage variables contribute to non-restrictive strategy only.
cDukes stage from Audit.
dDukes stage from CAS.
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tumour deposits use a size criterion in the Fifth Edition, while the
Sixth and Seventh Editions use a shape criterion to determine the
presence of mesenteric lymph node involvement (Doyle and
Bateman, 2012). Subdivisions of stage categories have been added,
and definitions of T4a and T4b have been reversed in the Seventh
Edition (Sobin et al, 2009). Except for the lymph node definition
change, none of the changes affect definitions of overall stage
grouping categories.
NBOCAP data allowed for single tumours to have several
treatment records. These records may hold conflicting information
on pathological T, N, and M components, presumably measured at
different points in the treatment journey. Therefore, the first part
of the algorithm applied to colorectal cancer was to establish a
hierarchy of NBOCAP treatment records based on their closeness
to diagnosis date. As a general rule, only records with treatment
procedures dated within 30 days before or after the date of
diagnosis were eligible to contribute with information on
pathological T, N, and M components. This was to avoid assigning
values of TNM associated with restaging and/or disease progres-
sion to what we define as stage at diagnosis. Of these records with
procedures dated between the ±30-day window from diagnosis,
the closest one to the date of diagnosis would be given priority over
information contained in subsequent treatment records, assuming
it contained a valid code for that variable. In cases where multiple
records of one tumour had the same procedure dates, the one with
lowest values of individual T, N, and M components would be
given priority, following a general rule of the TNM classification
(Sobin et al, 2009, p. 9). Information in subsequent treatment
records would only be used if such information was missing in the
previous one. Information on individual clinical T, N, and M
components from NBOCAP was the same in all treatment records
of any single tumour, as in CAS. Additional variables with
information on colorectal cancer-specific staging are listed in
Table 1. The full procedure to derive individual T, N, and M
components of stage for colorectal cancer is detailed in
Supplementary Appendix Figures S1–S3.
The second part of the algorithm for deriving overall stage
grouping using the non-restrictive strategy used additional
information from the colorectal cancer-specific Dukes classifica-
tion. As the Dukes classification is not directly equivalent to
specific combinations of individual T, N, and M components,
TNM summary stage variables from CAS were given priority over
Dukes staging, in the same order as individual T, N, and M
variables (pathological, followed by clinical and integrated). The
second part of the colorectal cancer stage algorithm is summarised
in Figures 2 and 3.
The staging algorithm applied to lung cancer. The first part of
the algorithm remains as described above, except that there were
no additional variables to inform individual T, N, and M
components in LUCADA (See Supplementary Appendix Figures
S6–S8).
The main challenge in adapting the algorithm to lung cancer
was the substantive modifications between the Sixth and Seventh
Editions of the TNM classification (Goldstraw et al, 2007):
definitions of some individual components of T and M as well as
of some categories of the stage grouping have changed (Mirsadraee
et al, 2012). We derived TNM stage grouping following definitions
of the Sixth and Seventh Editions of the TNM classification
separately. Most of these changes do not affect the overall TNM
stage grouping, therefore we chose to apply definitions of the
current Seventh Edition of TNM classification for the whole study
period (see Supplementary Appendix Figures S4 and S5).
Statistical analyses. We estimated age-standardised 5-year net
survival, stratified by stage, including a missing stage category, for
patients diagnosed in England between 2008 and 2012 and
followed up until end of 2013. Net survival represents survival
with cancer as the only potential cause of death by factoring out
mortality from other causes (expected mortality) (Pohar Perme
et al, 2012). Within the relative survival setting in which causes of
death are not available, the expected mortality was provided by life
tables from the England general population, namely, life tables by
age, sex, calendar year, and deprivation (London School of Hygiene
& Tropical Medicine, 2015). Net survival was estimated with the
non-parametric Pohar-Perme estimator (Pohar Perme et al, 2012)
implemented in the Stata program stns (Clerc-Urme`s et al, 2014).
We used the complete approach for survival analysis, as used for
national cancer survival statistics (Office for National Statistics,
2015). We used the International Cancer Survival Standard weights
for age standardisation, which categorises age into five groups (15–
44, 45–54, 55–64, 65–74, and 75–99 years of age) (Corazziari et al,
2004). We compared 5-year net survival between both versions of
the staging algorithm (restrictive and non-restrictive) for each
cancer.
RESULTS
The proportion of cases with valid information on individual T and
N components was comparable between cancer sites (Table 1).
Completeness of valid information on the M component varied
significantly between colorectal and lung cancer (41.2% vs 22.8%
missing M component, respectively Table 1). Of the 163 915
primary malignant colorectal tumours, 92 778 (56.6%) had valid
stage using the restrictive strategy and 137 429 (83.8%) using the
non-restrictive strategy. Of the 168 158 primary lung cancer cases,
128 866 (76.6%) had stage information with the restrictive strategy,
vs 135 666 (80.7%) with the non-restrictive strategy. Completeness
of derived stage improved over time for both cancer sites, as did
the difference in stage completeness between the restrictive and
non-restrictive strategies (Table 2).
Distribution of stage differed between strategies for colorectal
cancer (Table 2). Assuming equivalence between values of zero and
missing for N and M, as in the non-restrictive strategy, decreased
dramatically the overall missingness of TNM stage grouping for
colorectal cancer and affected the overall stage distribution. For
instance, 25 431 (27.4% of data with observed stage) tumours were
classified as stage III using the restrictive strategy and increased to
41 537 (30.2% of data with observed stage) using the non-
restrictive strategy, mainly owing to the assumption of equivalence
between missing and zero value of M in the first part of the
algorithm. This difference was less pronounced for lung cancer,
because of better completeness of the individual M component
(Table 1). Lung cancer stage distribution was comparable between
strategies (Table 2).
Using summary stage, variables in the non-restrictive strategy
did not considerably improve the completeness of stage for either
cancer site, indicating that most cases had fairly complete T, N, and
M information before reaching this step or had all stage variables
missing.
Age-standardised 1-year net survival for colorectal cancer was
significantly lower using the non-restrictive strategy for all stages,
particularly for the missing stage category. Differences in lung
cancer survival between the two strategies were negligible (Table 3;
Supplementary Appendix Figure S9). These figures reflect the
differences between both strategies and how incomplete the
individual stage components are.
DISCUSSION
This paper describes an algorithm to derive stage from
multiple data sources. Recording of stage is now one of the
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Clinical Commissioning Group Outcome Indicators in England.
However, it is rarely reported how this information is collected and
then integrated into stage categories. We aim to adopt a standard
approach to derive stage from multiple sources using a series of
hierarchical rules. We have adapted it to specific cancer sites to
illustrate its generalisability and highlight some data and cancer-
specific issues.
In our example, the use of TNM Fifth Edition for colorectal
cancer is justified to facilitate comparability of temporal trends
(Royal College of Pathologists, 2014). There is a perceived increase
in interobserver variability when assigning lymph node status
using the shape criterion of the Seventh TNM Edition, rather than
the size criterion of the Fifth Edition (Doyle and Bateman, 2012;
Royal College of Pathologists, 2014). In England, the RPC
recognises that some multidisciplinary teams – from which
Clinical Audit stage data may be collected – use the Seventh
Edition of TNM to stage colorectal cancers and that it might be
requested in particular cases, such as those enrolled in clinical
trials. There was poor individual information of the TNM edition
used for staging colorectal cancer in the data sets we used. Given
that there were some codes that are valid in TNM Seventh but not
in TNM Fifth, we remain uncertain that all cases were staged using
the Fifth Edition of TNM. There is conflicting evidence on the
effect of using different editions of the TNM classification on the
final staging (Nagtegaal et al, 2011; Doyle and Bateman, 2012).
Nonetheless, comparing categories using different TNM editions
may lead to stage migration, complicating comparisons of stage-
specific outcomes. In contrast, the lung cancer data sets, in
particular the Clinical Audit data, consistently reported an
individual indicator of the edition of TNM used.
Distribution of colorectal cancer stage and stage-specific
survival differed between strategies to define summary stage.
Survival was lower for all stage categories using the non-restrictive
strategy. Imputing all cases with missing M and/or N to a value of
zero, as in the non-restrictive strategy, relies on very strong
assumptions and may lead to misclassification, biased stage-
specific survival estimates, and overly narrow variances. The
missing stage categories contain a mixture of various stages,
even though on average their prognosis is poorer than
observed stage. The real stage distribution within the missing
categories is different between strategies, as is their survival. The
survival discrepancy between strategies was negligible for lung
M
96 399 
not missing 
(58.8%)
115 130
not missing 
(70.2%)
116 008
not missing 
(70.8%)
N
Yes
Yes
Yes
Yes
Yes
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No
Stage=4 31 224(19.0%)
Initial count:
163 915
(100%)
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71 137
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Stage=3
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T=3 or 4
N=1 or 2M=0
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T
Figure 2. Deriving stage for colorectal cancer using the restrictive strategy, England, 2008–2012. Abbreviations: T¼ tumour; N¼ lymph nodes;
M¼distant metastases.
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cancer. This is because there was more complete information on
individual M component for lung (77.2%) than for colorectal
cancer (58.8%). The restrictive approach is more conservative and
keeps open, when necessary, the possibility of using specific
approaches to deal with missing data, such as multiple imputation
(White et al, 2011).
M N T
116 008
not missing
(70.8%)
Initial count:
163 915
(100%)
31 224
(19.0%)
39 908
(24.3%)
36 433
(22.2%)
21 325
(13.0%)
38
(0.02%)
5
(0.003%)
1189
(0.7%)
2206
(1.3%)
1098
(0.7%)
4003
(2.4%)
26 486
(16.2%)
Stage=CAS
Dukes
Stage=NBOCAP
cDukes
Stage=NBOCAP
pDukes
Stage=CAS
iStage
Stage=CAS
cStage
Stage=CAS
pStage
  CAS pStage
not missing
  CAS cStage
not missing
  CAS iStage
not missing
  NBOCAP pDukes
not missing
  NBOCAP cDukes
not missing
CAS Dukes
not missing
Stage missing
Stage=1
Stage=2
Stage=3
Stage=4M=1 Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
No
No
No
No
M=0 or
missing
N=0 or
missing
N=1 or 2
T=3 or 4
T=1 or 2
115 130
not missing
(70.2%)
96 399
not missing
(58.8%)
Figure 3. Deriving stage for colorectal cancer using the non-restrictive strategy, England, 2008–2012. Abbreviations: CAS¼Cancer Analysis
System; cDukes¼ clinical Dukes staging; cStage¼ clinical TNM stage; iStage¼ integrated TNM stage; M¼distant metastases; N¼ lymph nodes;
NBOCAP¼National Bowel Cancer Project; pDukes¼pathological Dukes staging; pStage¼pathological TNM stage; T¼ tumour.
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A particular limitation arises when applying the algorithm for
staging tumours receiving neoadjuvant therapy. Pathological
stage components are collected after neoadjuvant treatment,
thus downgrading may occur. This issue may be addressed by
making specific rules to deal with such tumours. This was not
possible in our data given that information on neoadjuvant
therapy is missing in the vast majority of cases from all available
sources. Differences in aggressiveness of diagnostic investigation
may also affect the comparability of stage-specific outcomes
(Allemani et al, 2013).
We acknowledge potential limitations and have discussed the
data issues and our assumptions. We encountered several issues in
relation to coding of stage variables, inconsistencies in use of
editions of TNM classification, conflicting stage information for
single tumours, and a high proportion of missing data. We believe
these may arise in other settings and data sets and have tried to
address them in a transparent way, useful for other users of cancer
staging information.
We have applied the algorithm to two cancer sites in a single
country but aim for the hierarchical rules to be adaptable for
other cancer sites and data sources in different countries, as the
issue of inconsistently defined and reported stage categories is
widespread in the current population-based cancer research
(Ciccolallo et al, 2005; Walters et al, 2013a). The outcome will
depend heavily on the quality of the specific data source but the
general approach of prioritising information of highest quality,
reporting sources of individual TNM variables, and reporting of
assumptions when dealing with missing or inconsistent data is
relevant to any cancer research using stage information.
Descriptive results such as reported in Tables 1 and 2 are helpful
Table 2. Overall stage grouping by cancer, year of diagnosis, and staging strategy
Year of diagnosis
2008
count (%*)
2009
count (%*)
2010
count (%*)
2011
count (%*)
2012
count (%*)
Total
count (%*)
Colorectal cancer
Non-restrictive strategy
Missing stage 6996 (22.1) 6408 (19.8) 5114 (15.7) 4777 (14.3) 3191 (9.4) 26 486 (16.2)
Observed stage 24 630 (77.9) 25 939 (80.2) 27 518 (84.3) 28 708 (85.7) 30 634 (90.6) 137 429 (83.8)
I 3774 (15.3) 4159 (16.0) 4602 (16.7) 5043 (17.6) 5803 (18.9) 23 381 (17.0)
II 7631 (31.0) 7612 (29.3) 7764 (28.2) 7944 (27.7) 8195 (26.8) 39 146 (28.5)
III 7890 (32.0) 8212 (31.7) 8495 (30.9) 8508 (29.6) 8432 (27.5) 41 537 (30.2)
IV 5335 (21.7) 5956 (23.0) 6657 (24.2) 7213 (25.1) 8204 (26.8) 33 365 (24.3)
Restrictive strategy
Missing stage 20 948 (66.2) 19 360 (59.9) 15 071 (46.2) 10 749 (32.1) 5009 (14.8) 71 137 (43.4)
Observed stage 10 678 (33.8) 12 987 (40.1) 17 561 (53.8) 22 736 (67.9) 28 816 (85.2) 92 778 (56.6)
I 1046 (9.8) 1434 (11.0) 2333 (13.3) 3637 (16.0) 5117 (17.8) 13 567 (14.6)
II 2175 (20.4) 2684 (20.7) 4169 (23.7) 5883 (25.9) 7645 (26.5) 22 556 (24.3)
III 2759 (25.8) 3455 (26.6) 4839 (27.6) 6408 (28.2) 7970 (27.7) 25 431 (27.4)
IV 4698 (44.0) 5414 (41.7) 6220 (35.4) 6808 (29.9) 8084 (28.1) 31 224 (33.7)
Total 31 626 32 347 32632 33485 33 825 163 915
Lung cancer
Non-restrictive strategy
Missing stage 11 498 (35.9) 8242 (25.0) 5622 (16.8) 3938 (11.4) 2441 (6.9) 31 741 (18.9)
Observed stage 20 509 (64.1) 24 765 (75.0) 27 846 (83.2) 30 463 (88.6) 32 834 (93.1) 136 417 (81.1)
I 2888 (14.1) 3560 (14.4) 3713 (13.3) 4092 (13.4) 4871 (14.8) 19 124 (14.0)
II 1303 (6.4) 1661 (6.7) 2221 (8.0) 2509 (8.2) 2764 (8.4) 10 458 (7.7)
III 6338 (30.9) 7204 (29.1) 7030 (25.2) 7211 (23.7) 7623 (23.2) 35 406 (26.0)
IV 9980 (48.7) 12 340 (49.8) 14 882 (53.4) 16 651 (54.7) 17 576 (53.5) 71 429 (52.4)
Restrictive strategy
Missing stage 13 661 (42.7) 10 143 (30.7) 7321 (21.9) 5121 (14.9) 3046 (8.6) 39 292 (23.4)
Observed stage 18 346 (57.3) 22 864 (69.3) 26 147 (78.1) 29 280 (85.1) 32 229 (91.4) 128 866 (76.6)
I 2223 (12.1) 2952 (12.9) 3237 (12.4) 3781 (12.9) 4703 (14.6) 16 896 (13.1)
II 1060 (5.8) 1455 (6.4) 2030 (7.8) 2383 (8.1) 2696 (8.4) 9624 (7.5)
III 5357 (29.2) 6434 (28.1) 6531 (25.0) 6894 (23.5) 7437 (23.1) 32 653 (25.3)
IV 9706 (52.9) 12 023 (52.6) 14 349 (54.9) 16 222 (55.4) 17 393 (54.0) 69 693 (54.1)
Total 32 007 33 007 33468 34401 35 275 168 158
Note: %*: Percentages for stages I to IV represent the proportion of observed stage data, excluding observations with missing stage. Colorectal and lung cancer diagnoses in England, 2008–2012.
Table 3. Age-standardised estimates of 1- and 5-year net
survival by cancer, stage, and staging strategy
Non-restrictive
staging strategy
Restrictive
staging strategy
Stage NS (CI) NS (CI)
Colorectal cancer
One-year net survival
I 0.979 (0.976, 0.981) 0.982 (0.978, 0.985)
II 0.936 (0.933, 0.939) 0.949 (0.945, 0.952)
III 0.880 (0.877, 0.883) 0.898 (0.893, 0.902)
IV 0.495 (0.489, 0.501) 0.510 (0.504, 0.515)
Missing 0.605 (0.599, 0.612) 0.777 (0.774, 0.780)
Five-year net survival
I 0.952 (0.944, 0.960) 0.957 (0.945, 0.969)
II 0.849 (0.843, 0.855) 0.861 (0.852, 0.871)
III 0.638 (0.632, 0.645) 0.665 (0.655, 0.674)
IV 0.152 (0.146, 0.157) 0.158 (0.152, 0.164)
Missing 0.414 (0.406, 0.423) 0.619 (0.614, 0.624)
Lung cancer
One-year net survival
I 0.843 (0.837, 0.848) 0.852 (0.846, 0.858)
II 0.685 (0.675, 0.695) 0.693 (0.683, 0.704)
III 0.431 (0.425, 0.437) 0.439 (0.433, 0.445)
IV 0.182 (0.179, 0.185) 0.183 (0.180, 0.186)
Missing 0.256 (0.250, 0.262) 0.298 (0.293, 0.303)
Five-year net survival
I 0.542 (0.531, 0.554) 0.541 (0.529, 0.554)
II 0.325 (0.310, 0.340) 0.325 (0.309, 0.341)
III 0.099 (0.094, 0.104) 0.100 (0.095, 0.105)
IV 0.025 (0.024, 0.027) 0.026 (0.024, 0.028)
Missing 0.093 (0.088, 0.098) 0.125 (0.120, 0.130)
Abbreviations: CI, confidence interval; NS, net survival. Diagnoses in England, 2008–2012.
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in understanding the origins of summary stage and the reasons
for shifts in stage distributions.
Validity of the information contained in cancer records
remains a general issue. We believe it should be mandatory to
have a relevant clinician at the health-care provider level
ensuring that data collected are complete and truly reflect the
information clinical decisions are based on. For each cancer
case, it should be clear what classification was used to
assign stage variables. As skilled clinicians are needed to
collect and use stage information to make adequate medical
decisions, there is also the need of people with standardised
skills for recording and compiling of clinical information
from medical records. The National Health System should
make an effort to train and support such a workforce. Complete
and accurate stage information is essential to assess cancer
control policy and to understand inequalities in cancer
management and cancer survival, at both national and interna-
tional levels. We encourage cancer registries and health-care
providers to clearly document the process for deriving stage
grouping and reporting any data quality checks to validate this
information. This information should be readily available for
researchers.
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